Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205:e18–47. https://doi.org/10.1164/rccm.202202-0399ST.

Article  PubMed  PubMed Central  Google Scholar 

Alsomali H, Palmer E, Aujayeb A, Funston W. Early diagnosis and treatment of idiopathic pulmonary fibrosis: a narrative review. Pulmonary Therapy. 2023;9:177–93. https://doi.org/10.1007/s41030-023-00216-0.

Article  PubMed  PubMed Central  Google Scholar 

Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22:197. https://doi.org/10.1186/s12931-021-01791-z.

Article  PubMed  PubMed Central  Google Scholar 

Phan THG, Paliogiannis P, Nasrallah GK, Giordo R, Eid AH, Fois AG, et al. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cell Mol Life Sci. 2021;78:2031–57. https://doi.org/10.1007/s00018-020-03693-7.

Article  CAS  PubMed  Google Scholar 

Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Investig. 2021;131. https://doi.org/10.1172/jci143226.

Tran S, Ksajikian A, Overbey J, Li P, Li Y. Pathophysiology of pulmonary fibrosis in the context of COVID-19 and implications for treatment: a narrative review. Cells. 2022;11. https://doi.org/10.3390/cells11162489.

Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med. 2005;172:417–22. https://doi.org/10.1164/rccm.200501-017PP.

Article  PubMed  PubMed Central  Google Scholar 

Kuwano K, Hagimoto N, Maeyama T, Fujita M, Yoshimi M, Inoshima I, et al. Mitochondria-mediated apoptosis of lung epithelial cells in idiopathic interstitial pneumonias. Lab Invest. 2002;82:1695–706. https://doi.org/10.1097/01.lab.0000045084.81853.76.

Article  CAS  PubMed  Google Scholar 

Cantin AM, North SL, Fells GA, Hubbard RC, Crystal RG. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Investig. 1987;79:1665–73. https://doi.org/10.1172/jci113005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zemans RL, Henson PM, Henson JE, Janssen WJ. Conceptual approaches to lung injury and repair. Annals Am Thorac Soc. 2015;12(Suppl 1):S9–15. https://doi.org/10.1513/AnnalsATS.201408-402MG.

Article  Google Scholar 

Malaviya R, Kipen HM, Businaro R, Laskin JD, Laskin DL. Pulmonary toxicants and fibrosis: innate and adaptive immune mechanisms. Toxicol Appl Pharmcol. 2020;409:115272. https://doi.org/10.1016/j.taap.2020.115272.

Article  CAS  Google Scholar 

Heukels P, Moor CC, von der Thüsen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79–91. https://doi.org/10.1016/j.rmed.2018.12.015.

Article  CAS  PubMed  Google Scholar 

Hill C, Jones MG, Davies DE, Wang Y. Epithelial-mesenchymal transition contributes to pulmonary fibrosis via aberrant epithelial/fibroblastic cross-talk. J lung Health Dis. 2019;3:31–5.

Article  PubMed  PubMed Central  Google Scholar 

Ye Z, Hu Y. TGF–β1: gentlemanly orchestrator in idiopathic pulmonary fibrosis (review). Int J Mol Med. 2021;48:132. https://doi.org/10.3892/ijmm.2021.4965.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rahimi RA, Andrianifahanana M, Wilkes MC, Edens M, Kottom TJ, Blenis J, et al. Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta. Cancer Res. 2009;69:84–93. https://doi.org/10.1158/0008-5472.Can-08-2146.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168:960–76. https://doi.org/10.1016/j.cell.2017.02.004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buerger C. Epidermal mTORC1 signaling contributes to the pathogenesis of Psoriasis and could serve as a therapeutic target. Front Immunol. 2018;9:2786. https://doi.org/10.3389/fimmu.2018.02786.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marques-Ramos A, Cervantes R. Expression of mTOR in normal and pathological conditions. Mol Cancer. 2023;22:112. https://doi.org/10.1186/s12943-023-01820-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Das A, Reis F, Maejima Y, Cai Z, Ren J. mTOR Signaling in Cardiometabolic Disease, Cancer, and aging. Oxidative Med Cell Longev. 2017;2017:6018675. https://doi.org/10.1155/2017/6018675.

Article  CAS  Google Scholar 

Lawrence J, Nho R. The role of the mammalian target of Rapamycin (mTOR) in Pulmonary Fibrosis. Int J Mol Sci. 2018;19. https://doi.org/10.3390/ijms19030778.

Wu X, Xu Y, Liang Q, Yang X, Huang J, Wang J, et al. Recent advances in dual PI3K/mTOR inhibitors for Tumour Treatment. Front Pharmacol. 2022;13:875372. https://doi.org/10.3389/fphar.2022.875372.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li R, Zou X, Huang H, Yu Y, Zhang H, Liu P et al. HMGB1/PI3K/Akt/mTOR signaling participates in the pathological process of Acute Lung Injury by regulating the maturation and function of dendritic cells. 2020; 11. https://doi.org/10.3389/fimmu.2020.01104.

Woodcock HV, Eley JD, Guillotin D, Platé M, Nanthakumar CB, Martufi M, et al. The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nat Commun. 2019;10:6. https://doi.org/10.1038/s41467-018-07858-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Cui JT. Inhibition of Bcl-2 potentiates AZD-2014-induced anti-head and neck squamous cell carcinoma cell activity. Biochem Biophys Res Commun. 2016;477:607–13. https://doi.org/10.1016/j.bbrc.2016.06.100.

Article  CAS  PubMed  Google Scholar 

Huo HZ, Zhou ZY, Wang B, Qin J, Liu WY, Gu Y. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014;443:406–12. https://doi.org/10.1016/j.bbrc.2013.11.099.

Article  CAS  PubMed  Google Scholar 

Zheng B, Mao JH, Qian L, Zhu H, Gu DH, Pan XD, et al. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma. Cancer Lett. 2015;357:468–75. https://doi.org/10.1016/j.canlet.2014.11.012.

Article  CAS  PubMed  Google Scholar 

Tirunavalli SK, Gourishetti K, Kotipalli RSS, Kuncha M, Kathirvel M, Kaur R, et al. Dehydrozingerone ameliorates Lipopolysaccharide induced acute respiratory distress syndrome by inhibiting cytokine storm, oxidative stress via modulating the MAPK/NF-κB pathway. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2021;92:153729. https://doi.org/10.1016/j.phymed.2021.153729.

Article  CAS  Google Scholar 

Shaikh TB, Kuncha M, Andugulapati SB, Sistla R. Dehydrozingerone alleviates pulmonary fibrosis via inhibition of inflammation and epithelial-mesenchymal transition by regulating the Wnt/β-catenin pathway. Eur J Pharmacol. 2023;953:175820. https://doi.org/10.1016/j.ejphar.2023.175820.

Article  CAS  PubMed  Google Scholar 

Liu MH, Lin AH, Ko HK, Perng DW, Lee TS, Kou YR. Prevention of Bleomycin-Induced Pulmonary inflammation and fibrosis in mice by Paeonol. Front Physiol. 2017;8:193. https://doi.org/10.3389/fphys.2017.00193.

Article  PubMed  PubMed Central  Google Scholar 

Cross J, Stenton GR, Harwig C, Szabo C, Genovese T, Di Paola R, et al. AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis. Br J Pharmacol. 2017;174:3045–57. https://doi.org/10.1111/bph.13934.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Madala SK, Maxfield MD, Davidson CR, Schmidt SM, Garry D, Ikegami M, et al. Rapamycin regulates Bleomycin-Induced Lung damage in SP-C-Deficient mice. Pulmonary Med. 2011;2011:653524. https://doi.org/10.1155/2011/653524.

Article  CAS  Google Scholar 

Tirunavalli SK, Kuncha M, Sistla R, Andugulapati SB. Targeting TGF-β/periostin signaling by sesamol ameliorates pulmonary fibrosis and improves lung function and survival. J Nutr Biochem. 2023;116:109294. https://doi.org/10.1016/j.jnutbio.2023.109294.

Article  CAS  PubMed  Google Scholar 

Nakatsuka Y, Yaku A, Handa T, Vandenbon A, Hikichi Y, Motomura Y et al. Profibrotic function of pulmonary group 2 innate lymphoid cells is controlled by regnase-1. Eur Respir J. 2021; 57:2000018. https://doi.org/10.1183/13993003.00018-2020.

Tirunavalli SK, Pramatha S, Eedara AC, Walvekar KP, Immanuel C, Potdar P, et al. Protective effect of β-glucan on poly(I:C)-induced acute lung injury/inflammation: therapeutic implications of viral infections in the respiratory system. Life Sci. 2023;330:122027. https://doi.org/10.1016/j.lfs.2023.122027.

Article  CAS  PubMed  Google Scholar 

Andugulapati SB, Gourishetti K, Tirunavalli SK, Shaikh TB, Sistla R. Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems. Phytomedicine: Int J Phytotherapy Phytopharmacology. 2020;78:153298. https://doi.org/10.1016/j.phymed.2020.153298.

Article  CAS  Google Scholar 

Bian F, Lan Y-W, Zhao S, Deng Z, Shukla S, Acharya A, et al. Lung endothelial cells regulate pulmonary fibrosis through FOXF1/R-Ras signaling. Nat Commun. 2023;14:2560. https://doi.org/10.1038/s41467-023-38177-2.

Article  CAS  PubMed  PubMed Central